Rosuvastatin in Order to Induce Preeclampsia Resolution in Severe PET up to 48 Hours Following Delivery
Status:
Unknown status
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Prospective randomized single blind trial. Study population are women diagnosed with severe
pre-eclampsia during singleton pregnancy, between 24+0 weeks and 41+6 weeks gestational age.
The purpose of the study is to evaluate the effect of Rosuvastatin on the severe preeclampsia
resolution at 48 hours after delivery. After screening and signing an informed consent form,
before entering delivery room, a randomization 1:1 will be carried. 50 women will be in the
treatment arm while 50 will be in the control arm. Both groups will be treated according to
ACOG (The American College of Obstetricians and Gynecologists has the following clinical
guidelines related to deliveries before 39 weeks) guidelines. In addition, following
randomization experimental group will be treated with Rosuvastatin 40mg that will be
administrated orally with or without food. Treatment will be carried within the first hour
following delivery. Another dose will be given 24 hours after first administration. Control
group will be treated with placebo.